PDCD1 and neoplasm: Importantly, administration of anti-PD1 significantly delayed recurrence in mice treated with antigen-specific T-cells in the biomaterial (OT1+anti-PD1 median survival 110 days, p < 0.05 vs. 2C+anti-PD1 median survival 74 days, p < 0.05 vs. OT1 median survival 84 days), and this resulted in long-term tumor cures (Figure 5Biv–v).